特应性皮炎重磅消息！乌帕替尼3期临床疗效击败达必妥！

Atopic dermatitis (AD), also known as "atopic dermatitis" and "atopic eczema", is a chronic, relapsing, inflammatory skin disease whose typical clinical features are significant dry skin and itching. AD is usually combined with allergic diseases such as food allergy, asthma and allergic rhinitis, and has an atopic constitution. Currently, the number of AD patients worldwide is as high as 230 million, and the prevalence of adult AD in different countries and regions is approximately 2.1% to 4.9% [1]. Approximately 50% of all patients develop the disease before 1 year old, and up to 90% of patients present with mild to moderate symptoms. It is a selective JAK1 inhibitor. Its selectivity for JAK1 is 60 times that of JAK2 and 100 times that of JAK3. It has a half-life of 6 to 16 hours and is used to treat systemic autoimmune inflammatory diseases including inflammatory bowel disease.

A recent phase 3 clinical study of upadatinib showed that the drug’s efficacy has surpassed that of Dalbitux!

According to efficacy data from the Phase 3b Heads Up study, upadatinib (30 mg, oral, once daily) has a better therapeutic effect on the primary endpoint than Dalbitux (300 mg, subcutaneous injection, once weekly): at 16 weeks of treatment, a higher proportion of patients achieved EASI75 (eczema area and severity index improved by at least 75%) (71% vs 61%). In addition, upadatinib was also shown to be superior to Dalbitux in all secondary endpoints, including additional skin clearance and anti-itch measures.

Studies have shown that upadatinib dose adjustment is not required in patients with impaired renal function, and high-fat diet has no effect on the drug metabolism of uppatinib; strong CYP3A inhibitors and broad CYP inducers have weak and moderate effects on the pharmacokinetics of uppatinib, respectively. When combined with such drugs, attention should be paid to dose adjustment.

Original source:[1]Vakharia PP, Chopra R, Silverberg JI. Systematic review of diagnostic criteria used in atopic dermatitis randomized controlled trials[J]. Am J Clin Dermatol, 2018, 19(1): 15-22.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.